{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/129298"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/129298","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Hydrogel platform to investigate progression of drug-resistant glioblastoma","abstract":"Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2025-10-19 without embargo terms","abstract_html":"Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2025-10-19 without embargo terms","abstract_has_math":false,"creators":["Kriuchkovskaia, Victoria Anatolyevna"],"institution":"University of Illinois Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemical Engineering","degree_department":null,"school":null,"contributors":["Harley, Brendan AC","Hergenrother, Paul J","Zhao, Huimin","Riggins, Rebecca B"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-05-02","date_published":"2025-05-02","updated_at":"2026-07-22T22:25:04Z","subjects":["Glioblastoma","Temozolomide","Drug resistance","Cancer Model","Biomaterials","Hydrogels","3D in vitro model","Drug response","Migration","Invasion"],"languages":["en","eng"],"rights":["Copyright 2025 Victoria Kriuchkovskaia"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2142/129298","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Harley, Brendan AC","Hergenrother, Paul J","Zhao, Huimin","Riggins, Rebecca B"]},{"key":"dc:creator","label":"Author","values":["Kriuchkovskaia, Victoria Anatolyevna"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-05-02","2025-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Glioblastoma","Temozolomide","Drug resistance","Cancer Model","Biomaterials","Hydrogels","3D in vitro model","Drug response","Migration","Invasion"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en","eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2025 Victoria Kriuchkovskaia"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2142/129298"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2025-10-19 without embargo terms","The student, Victoria Kriuchkovskaia, accepted the attached license on 2025-05-01 at 13:35.","The student, Victoria Kriuchkovskaia, submitted this Dissertation for approval on 2025-05-02 at 09:13.","This Dissertation was approved for publication on 2025-05-02 at 14:55.","DSpace SAF Submission Ingestion Package generated from Vireo submission #22155 on 2025-10-19 at 18:11:29","Acquired drug resistance in glioblastoma (GBM) presents a major clinical challenge and is a key contributor to its poor prognosis, with a median overall survival of less than 15 months. Current treatment strategies offer limited benefits to most patients, despite the use of an aggressive multi-modal treatment approach. The front-line chemotherapeutic agent, temozolomide (TMZ), fails to eradicate residual and highly invasive tumor cells following surgical resection and radiotherapy. While some patients initially respond positively to TMZ, GBM cells often develop resistance, leading to only a modest four-month increase in median overall survival with TMZ included in the treatment regimen. With no effective second-line therapy currently available, there is a pressing need for more clinically relevant in vitro GBM models that can elucidate the complex mechanisms underlying acquired TMZ resistance and inform the development of novel therapeutic interventions to combat this lethal malignancy. Indeed, many existing models for assessing drug response overlook the role of the extracellular matrix (ECM) and the broader tumor microenvironment (TME)—critical elements that contribute to the aggressive nature of GBM. Additionally, those that do consider these key factors often use supraphysiological drug concentrations, which can lead to misleading conclusions. Investigating how the standard-of-care treatment drives phenotypic and mechanistic changes in GBM progression within three-dimensional (3D) ECM models could uncover key insights for identifying novel therapeutic targets. This dissertation describes a bioengineering approach to develop increasingly sophisticated and physiologically relevant in vitro biomaterial models to systematically evaluate drug response in GBM. Herein, we report 3D engineered models of acquired TMZ resistance using two isogenically-matched GBM cell line pairs encapsulated in methacrylamide-functionalized gelatin (GelMA) hydrogels. We benchmark the responses of TMZ-resistant versus TMZ-sensitive cell lines within the GelMA-based ECM platform and further validate drug response at physiologically relevant TMZ concentrations. Our findings demonstrate changes in drug sensitivity, invasive capacity, and matrix-remodeling cytokine production resulting from acquired TMZ resistance. Additionally, this dissertation sheds light on the relationship between TMZ treatment and the go-or-grow plasticity of GBM cells. This platform lays the groundwork for future investigations into how key components of the GBM TME (e.g., vascular, stromal, immune, etc. niches) influence tumor response to therapeutic interventions. Although this platform primarily focuses on TMZ, it also examines other small-molecule therapeutic agents and discusses how the established model systems could be adapted to study alternative therapeutic modalities. By advancing our understanding of GBM progression following chemotherapy, this work proposes novel strategies to mitigate the devastating impact of GBM. Indeed, systematic evaluation of shifts in cellular response to front-line therapies has the potential to guide the development of more effective treatment strategies, and robust bioengineered 3D in vitro assays are uniquely positioned to probe the under-explored GBM TME in a systematic and accessible manner."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Hydrogel platform to investigate progression of drug-resistant glioblastoma"]}]}],"canonical_facts":{"dc:contributor":["Harley, Brendan AC","Hergenrother, Paul J","Zhao, Huimin","Riggins, Rebecca B"],"dc:creator":["Kriuchkovskaia, Victoria Anatolyevna"],"dc:date":["2025-05-02","2025-05"],"dc:description":["Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2025-10-19 without embargo terms","The student, Victoria Kriuchkovskaia, accepted the attached license on 2025-05-01 at 13:35.","The student, Victoria Kriuchkovskaia, submitted this Dissertation for approval on 2025-05-02 at 09:13.","This Dissertation was approved for publication on 2025-05-02 at 14:55.","DSpace SAF Submission Ingestion Package generated from Vireo submission #22155 on 2025-10-19 at 18:11:29","Acquired drug resistance in glioblastoma (GBM) presents a major clinical challenge and is a key contributor to its poor prognosis, with a median overall survival of less than 15 months. Current treatment strategies offer limited benefits to most patients, despite the use of an aggressive multi-modal treatment approach. The front-line chemotherapeutic agent, temozolomide (TMZ), fails to eradicate residual and highly invasive tumor cells following surgical resection and radiotherapy. While some patients initially respond positively to TMZ, GBM cells often develop resistance, leading to only a modest four-month increase in median overall survival with TMZ included in the treatment regimen. With no effective second-line therapy currently available, there is a pressing need for more clinically relevant in vitro GBM models that can elucidate the complex mechanisms underlying acquired TMZ resistance and inform the development of novel therapeutic interventions to combat this lethal malignancy. Indeed, many existing models for assessing drug response overlook the role of the extracellular matrix (ECM) and the broader tumor microenvironment (TME)—critical elements that contribute to the aggressive nature of GBM. Additionally, those that do consider these key factors often use supraphysiological drug concentrations, which can lead to misleading conclusions. Investigating how the standard-of-care treatment drives phenotypic and mechanistic changes in GBM progression within three-dimensional (3D) ECM models could uncover key insights for identifying novel therapeutic targets. This dissertation describes a bioengineering approach to develop increasingly sophisticated and physiologically relevant in vitro biomaterial models to systematically evaluate drug response in GBM. Herein, we report 3D engineered models of acquired TMZ resistance using two isogenically-matched GBM cell line pairs encapsulated in methacrylamide-functionalized gelatin (GelMA) hydrogels. We benchmark the responses of TMZ-resistant versus TMZ-sensitive cell lines within the GelMA-based ECM platform and further validate drug response at physiologically relevant TMZ concentrations. Our findings demonstrate changes in drug sensitivity, invasive capacity, and matrix-remodeling cytokine production resulting from acquired TMZ resistance. Additionally, this dissertation sheds light on the relationship between TMZ treatment and the go-or-grow plasticity of GBM cells. This platform lays the groundwork for future investigations into how key components of the GBM TME (e.g., vascular, stromal, immune, etc. niches) influence tumor response to therapeutic interventions. Although this platform primarily focuses on TMZ, it also examines other small-molecule therapeutic agents and discusses how the established model systems could be adapted to study alternative therapeutic modalities. By advancing our understanding of GBM progression following chemotherapy, this work proposes novel strategies to mitigate the devastating impact of GBM. Indeed, systematic evaluation of shifts in cellular response to front-line therapies has the potential to guide the development of more effective treatment strategies, and robust bioengineered 3D in vitro assays are uniquely positioned to probe the under-explored GBM TME in a systematic and accessible manner."],"dc:format":["application/pdf"],"dc:identifier":["https://hdl.handle.net/2142/129298"],"dc:language":["en","eng"],"dc:rights":["Copyright 2025 Victoria Kriuchkovskaia"],"dc:subject":["Glioblastoma","Temozolomide","Drug resistance","Cancer Model","Biomaterials","Hydrogels","3D in vitro model","Drug response","Migration","Invasion"],"dc:title":["Hydrogel platform to investigate progression of drug-resistant glioblastoma"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Chemical Engineering"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois Urbana-Champaign"]},"updated_at":"2026-07-22T22:25:04Z"}